StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
MGRO.V$0.49-2.00%
Fair $0.49+0.0%

MGRO.V

MustGrow Biologics Corp.

Basic Materials / Agricultural InputsTSXV

$0.49

-0.01 (-2.00%)

Fairly Valued+0.0%Fair Value $0.49Fund rank 26/100 · Data gapFallback financials|
SA 19/F
F-Score: 2/9
Low Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 18%

FCF escenarios

weak_data · normalized FCF $-3.6M · quality 46.7/100

Data gap 26/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 14/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

19/100

F

Piotroski

2/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 1unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Sector-specific commodity mid-cycle model required: targets are disabled until normalized cycle price/cost-curve/reserve data exists. ROE is -8.4%, below the 5% threshold
Thesis & Journal · MGRO.VLocal privado en este navegador · MustGrow Biologics Corp.
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$31M

P/E

N/A

•

EV/EBITDA

N/A

•

ROE

-837.0%

↓

Gross Margin

14.1%

↓

Debt/Equity

0.67

↑
52-Week Range$0
$0$1

TradingView lightweight chart

MGRO.V price, volumen y niveles de valoración

Último $0.490Periodo -86.2%
Fair value: $0.490

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+985.5%

FCF CAGR

—

FCF margin

-61.0%

FCF / Net income

0.70x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $8.3M · net income $-7.3M · FCF $-5.1M

2022-FY → 2025-FY

Gross margin

14.1%— pts

Operating margin

-75.5%+87671.5% pts

Net margin

-87.6%+85818.3% pts

FCF margin

-61.0%+50217.4% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$8.3M$8.3M$398018.00$4.7M$6479.00
Net Income$-7.3M$-7.3M$-4.9M$-676940.00$-5.6M
EBITDA$-6.9M$-6.9M$-4.9M$-804988.00$-5.6M
EPS-0.13-0.13-0.09-0.01-0.11
Gross Margin14.1%14.1%75.6%100.0%—
Operating Margin-75.5%-75.5%-1284.9%-17.1%-87746.9%
Net Margin-87.6%-87.6%-1228.3%-14.4%-85905.9%
Balance Sheet
Debt/Equity0.670.670.240.140.14
Current Ratio1.881.88———
Cash Flow
Free Cash Flow$-5.1M$-5.1M$-3.6M$-294764.00$-3.3M
Returns
ROE-837.0%-837.0%-225.3%-12.1%-106.2%
Valuation
P/B30.7230.7240.4312.9631.15
Growth & Yield
Revenue Growth1982.0%1982.0%-91.6%72630.4%—
EPS Growth-44.4%-44.4%-800.0%90.9%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -50.5%

Total return

-50.5%

Start / end P/E

n/dx → n/dx

EPS bridge

-0.09 → -0.13

Residual

-50.5%

EPS growthn/d
Multiple reratingn/d
Dividend+0.0%
Residual / FX / buybacks / cross-term-50.5%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.